Best practices for controlled ovarian stimulation in in vitro fertilization

Seminars in Reproductive Medicine

Volumn 33, Issue 2, 2015, Pages 77-82

  Jungheim, Emily S ^a   Meyer, Melissa F ^a   Broughton, Darcy E ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

controlled ovarian stimulation; gonadotropins; in vitro fertilization

Indexed keywords

GONADOTROPIN; FERTILITY PROMOTING AGENT;

ARTICLE; CONTROLLED OVARIAN STIMULATION; EXCITATION AND STIMULATION; FERTILIZATION IN VITRO; HUMAN; LIVE BIRTH; OBSERVATIONAL STUDY; OVARIAN RESERVE; PATIENT CARE; PATIENT DECISION MAKING; PHYSICIAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG EFFECTS; FEMALE; FERTILITY; INFERTILITY; MALE; OVARY; OVULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PROCEDURES; QUALITY CONTROL; STANDARDS; TREATMENT OUTCOME;

BENCHMARKING; FEMALE; FERTILITY; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY; MALE; OVARY; OVULATION; OVULATION INDUCTION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; TREATMENT OUTCOME;

EID: 84930008643     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0035-1546424     Document Type: Article

References (51)

1. Steptoe P. C., Edwards R. G. Birth after the reimplantation of a human embryo. Lancet: 1978; 2 8085 366
2. Jones H. W. Jr, Jones G. S., Andrews M. C., et al. The program for in vitro fertilization at Norfolk. Fertil Steril: 1982; 38 1 14 21
3. Jones H. W. Jr. The use of controlled ovarian hyperstimulation (COH) in clinical in vitro fertilization: the role of Georgeanna Seegar Jones. Fertil Steril: 2008; 90 5 e1 e3
4. Fritz M. A. (2011). Clinical Gynecologic Endocrinology and Infertility, 8th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins: 2011
5. Van Voorhis B. J., Thomas M., Surrey E. S., Sparks A. What do consistently high-performing in vitro fertilization programs in the U.S. do? Fertil Steril: 2010; 94 4 1346 1349
6. Beall S. A., DeCherney A. History and challenges surrounding ovarian stimulation in the treatment of infertility. Fertil Steril: 2012; 97 4 795 801
7. Gianaroli L., Racowsky C., Geraedts J., Cedars M., Makrigiannakis A., Lobo R. A. Best practices of ASRM and ESHRE: a journey through reproductive medicine. Fertil Steril: 2012; 98 6 1380 1394
8. Lyerly A. D., Steinhauser K., Voils C., et al. Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertil Steril: 2010; 93 2 499 509
9. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion. Fertil Steril: 2013; 99 3 663 666
10. Verpoest W., Fauser B. C., Papanikolaou E., et al. Chromosomal aneuploidy in embryos conceived with unstimulated cycle IVF. Hum Reprod: 2008; 23 10 2369 2371
11. Baart E. B., Martini E., Eijkemans M. J., et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod: 2007; 22 4 980 988
12. Kovacs P., Sajgo A., Kaali S. G., Pal L. Detrimental effects of high-dose gonadotropin on outcome of IVF: making a case for gentle ovarian stimulation strategies. Reprod Sci: 2012; 19 7 718 724
13. Labarta E., Bosch E., Alamá P., Rubio C., Rodrigo L., Pellicer A. Moderate ovarian stimulation does not increase the incidence of human embryo chromosomal abnormalities in in vitro fertilization cycles. J Clin Endocrinol Metab: 2012; 97 10 E1987 E1994
14. Trounson A., Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature: 1983; 305 5936 707 709
15. Wong K. M., Mastenbroek S., Repping S. Cryopreservation of human embryos and its contribution to in vitro fertilization success rates. Fertil Steril: 2014; 102 1 19 26
16. Jungheim E. S., Carson K. R., Brown D. Counseling and consenting women with cancer on their oncofertility options: a clinical perspective. Cancer Treat Res: 2010; 156 403 412
17. La Marca A., Sunkara S. K. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update: 2014; 20 1 124 140
18. Berkkanoglu M., Ozgur K. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril: 2010; 94 2 662 665
19. Nardo L. G., Bosch E., Lambalk C. B., Gelbaya T. A. Controlled ovarian hyperstimulation regimens: a review of the available evidence for clinical practice. Produced on behalf of the BFS Policy and Practice Committee. Hum Fertil (Camb): 2013; 16 3 144 150
20. Practice Committee of American Society for Reproductive Medicine, Birmingham, Alabama Gonadotropin preparations: past, present, and future perspectives. Fertil Steril: 2008; 90 (5, Suppl): S13 S20
21. Coomarasamy A., Afnan M., Cheema D., van der Veen F., Bossuyt P. M., van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod: 2008; 23 2 310 315
22. Lehert P., Schertz J. C., Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol: 2010; 8 112
23. van Wely M., Kwan I., Burt A. L., et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev: 2011; 2 CD005354
24. Wechowski J., Connolly M., Schneider D., McEwan P., Kennedy R. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril: 2009; 91 4 1067 1076
25. Propst A. M., Hill M. J., Bates G. W., Palumbo M., Van Horne A. K., Retzloff M. G. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril: 2011; 96 4 898 904
26. The European Recombinant Human LH Study Group Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab: 1998; 83 5 1507 1514
27. Youssef M. A., Al-Inany H. G., Aboulghar M., Mansour R., Abou-Setta A. M. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev: 2011; 4 CD003719
28. Awwad J. T., Farra C., Mitri F., Abdallah M. A., Jaoudeh M. A., Ghazeeri G. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study. Reprod Biomed Online: 2013; 26 1 88 92
29. Fox J. H., Jackson K. V., Rein M. S., Hornstein M. D., Clarke R. N., Friedman A. J. A randomized clinical trial to evaluate the clinical effects of split- versus single-dose human menopausal gonadotropins in an assisted reproductive technology program. Fertil Steril: 1996; 65 3 598 602
30. Sharara F. I., Collins M. G., Abdo G. Decreased gonadotropin requirements in once daily compared to twice daily administration: a prospective, randomized study. J Assist Reprod Genet: 2012; 29 4 321 324
31. Dahan M. H., Lathi R. B. Twice-daily dosing of gonadotropins does not improve embryo quality during in vitro fertilization cycles in women with polycystic ovary syndrome, when compared to once-daily dosing: a pilot study. Arch Gynecol Obstet: 2014; 289 5 1113 1118
32. Devroey P., Boostanfar R., Koper N. P., Mannaerts B. M., Ijzerman-Boon P. C., Fauser B. C.; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod: 2009; 24 12 3063 3072
33. Boostanfar R., Mannaerts B., Pang S., Fernandez-Sanchez M., Witjes H., Devroey P.; Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone. Fertil Steril: 2012; 97 6 1351 1358
34. Azim A. A., Costantini-Ferrando M., Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol: 2008; 26 16 2630 2635
35. Fiedler K., Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol: 2012; 10 32
36. Leitao V. M., Moroni R. M., Seko L. M., Nastri C. O., Martins W. P. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril: 2014; 101 3 664 675
37. Mathur R., Alexander C. J., Yano J., Trivax B., Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol: 2008; 199 6 596 609
38. Reynolds K. A., Omurtag K. R., Jimenez P. T., Rhee J. S., Tuuli M. G., Jungheim E. S. Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. Hum Reprod: 2013; 28 11 2981 2989
39. Tso L. O., Costello M. F., Albuquerque L. E., Andriolo R. B., Macedo C. R. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev: 2014; 11 CD006105
40. Youssef M. A., Van der Veen F., Al-Inany H. G., et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev: 2014; 10 CD008046
41. Bentov Y., Hannam T., Jurisicova A., Esfandiari N., Casper R. F. Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment. Clin Med Insights Reprod Health: 2014; 8 31 36
42. Bromer J. G., Cetinkaya M. B., Arici A. Pretreatments before the induction of ovulation in assisted reproduction technologies: evidence-based medicine in 2007. Ann N Y Acad Sci: 2008; 1127 31 40
43. Meldrum D. R., Fisher A. R., Butts S. F., Su H. I., Sammel M. D. Acupuncture-help, harm, or placebo? Fertil Steril: 2013; 99 7 1821 1824
44. Nardo L. G., El-Toukhy T., Stewart J., Balen A. H., Potdar N. British Fertility Society Policy and Practice Committee: Adjuvants in IVF: evidence for good clinical practice. Hum Fertil (Camb): 2014; 1 14
45. Polanski L. T., Barbosa M. A., Martins W. P., et al. Interventions to improve reproductive outcomes in women with elevated natural killer cells undergoing assisted reproduction techniques: a systematic review of literature. Hum Reprod: 2014; 29 1 65 75
46. Allersma T., Farquhar C., Cantineau A. E. Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database Syst Rev: 2013; 8 CD010550
47. Sato A., Otsu E., Negishi H., Utsunomiya T., Arima T. Aberrant DNA methylation of imprinted loci in superovulated oocytes. Hum Reprod: 2007; 22 1 26 35
48. Barnhart K. T. Introduction: are we ready to eliminate the transfer of fresh embryos in in vitro fertilization? Fertil Steril: 2014; 102 1 1 2
49. van Tilborg T. C., Eijkemans M. J., Laven J. S., et al. The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. BMC Womens Health: 2012; 12 29
50. Politi M. C., Lewis C. L., Frosch D. L. Supporting shared decisions when clinical evidence is low. Med Care Res Rev: 2013; 70 (1, Suppl): 113S 128S
51. van Peperstraten A. M., Hermens R. P., Nelen W. L., et al. Deciding how many embryos to transfer after in vitro fertilisation: development and pilot test of a decision aid. Patient Educ Couns: 2010; 78 1 124 129